Crinetics Pharmaceuticals Inc
CRNX
Market Cap$3.16B
Close$
$0.81
97.5% downside
Current Fair Value
97.5% downsideOvervalued by 97.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.16 Billion |
|---|---|
| Enterprise Value | $2.95 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.69 |
| Beta | 0.38 |
| Outstanding Shares | 91,494,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.35 |
|---|---|
| PEG | -30.7 |
| Price to Sales | - |
| Price to Book Ratio | 2.34 |
| Enterprise Value to Revenue | 2839.53 |
| Enterprise Value to EBIT | -9.58 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Crinetics Pharmaceuticals Inc
CEO: R. Scott Struthers